Treatment of advanced ovarian cancer: A randomised trial comparing adriamycin or 4′epi‐adriamycin in combination with cisplatin and cyclophosphamide

Fifty-one patients with ovarian cancer were entered in a randomised trial comparing treatment with cisplatin + adriamycin + cyclophosphamide (PAC) to cisplatin + 4'epi-adriamycin + cyclophosphamide (PEC). Complete response rates for the two treatment arms were similar (9/27 PAC, 14/24 PEC). Patients with less than 2 cm residual disease had significantly higher rate of complete remission than those with greater than 2 cm residual disease. Cardiotoxicity was significantly less in the PEC-treated group (0/24) as compared with the PAC-treated group (6/27, chi2 = 4.09, p less than 0.05).